This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medicis Turns Loss Into Win

Although it lost the contest, Medicis (MRX) has come away with a potentially attractive parting gift.

The Scottsdale, Ariz., dermatology products company has acquired the rights to an experimental Botox-like drug from French drugmaker Ipsen, giving Medicis another chance to expand its cosmetic skin-care operations.

The news, announced Monday evening, prompted shares of Medicis to jump $3.21, or 11%, to $32.34 in early trading Tuesday.

The deal with Ipsen for the drug Reloxin will provide competition for Botox-maker Allergan (AGN - Get Report), which outbid Medicis to acquire Inamed (IMDC), a maker of dermatology products and breast implants.

Medicis coveted Inamed primarily because Inamed had the licensing rights to Reloxin, which is still in clinical trials. When Allergan won the battle for Inamed, the Federal Trade Commission said it had to relinquish its rights to Reloxin.

The rights reverted to Ipsen, which then signed a deal with Medicis to develop Reloxin in the U.S., Canada and Japan. The drug's brand name outside these markets is Dysport.

Medicis declined to provide details about the Reloxin transaction, saying it would wait until Allergan officially acquires Inamed. Allergan's tender offer has been extended several times during the last few months. The next and final deadline is March 17.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRX $0.00 0.00%
IMDC $0.02 0.00%
AGN $319.76 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs